Proteins and Peptides

26 May 2017 Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
26 May 2017 FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications
25 May 2017 Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
24 May 2017 Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference
23 May 2017 Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
23 May 2017 Dompé Receives Positive CHMP Opinion in Europe For Oxervate® (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis
23 May 2017 Atox Bio's Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
23 May 2017 Positive Phase 2a results with microdoses of dasiglucagon support use in a dual-hormone artificial pancreas system
23 May 2017 Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
22 May 2017 AM-Pharma Completes Patient Recruitment of Recombinant Human Alkaline Phosphatase (recAP) Phase II Trial in Acute Kidney Injury
22 May 2017 Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
21 May 2017 Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
19 May 2017 Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial
18 May 2017 Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
17 May 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity
17 May 2017 Cinfa Biotech announces positive top-line data from second clinical study with pegfilgrastim biosimilar candidate B12019
16 May 2017 ALPHAEON Submits Biologics License Application for DWP-450 Neuromodulator
15 May 2017 Long-term Data Confirm Benefits of Treatment with Strensiq(R) (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years
11 May 2017 SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
10 May 2017 Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
09 May 2017 Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies
08 May 2017 Araim Pharmaceuticals' Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis
05 May 2017 Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery
04 May 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity
03 May 2017 NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing